Back to today’s briefing

Story perspectives

CEPI Invests $13.38M in Innovative Nipah Virus Vaccine

4/1/2025

50 9

Summary

Story summary

CEPI is set to invest $13.38 million in Gennova Biopharmaceuticals to create a groundbreaking self-amplifying mRNA vaccine for the lethal Nipah virus, known for its staggering 75% fatality rate. Partnering with Houston Methodist Research Institute, they will harness AI to pinpoint vaccine targets, with preclinical trials taking place in India to combat previous outbreaks.

1 of 1

Story summary

CEPI is set to invest $13.38 million in Gennova Biopharmaceuticals to create a groundbreaking self-amplifying mRNA vaccine for the lethal Nipah virus, known for its staggering 75% fatality rate. Partnering with Houston Methodist Research Institute, they will harness AI to pinpoint vaccine targets, with preclinical trials taking place in India to combat previous outbreaks.